Hariharan Nisha, Brunson Ann, Mahajan Anjlee, Keegan Theresa H M, Wun Ted
Department of Internal Medicine and.
Center for Oncology Hematology Outcomes Research and Training, Division of Hematology Oncology, University of California, Davis School of Medicine, Davis, CA; and.
Blood Adv. 2020 Mar 10;4(5):793-802. doi: 10.1182/bloodadvances.2019000940.
Bleeding is a known complication of sickle cell disease (SCD) and includes hemorrhagic stroke, hematuria, and vitreous hemorrhage. However, the incidence of bleeding events in patients with SCD has not been well described. We present a retrospective, population-based study examining the cumulative incidence of bleeding in 6423 patients with SCD from 1991 to 2014. We also studied risk factors associated with bleeding and the effects of bleeding on mortality, using Cox proportional hazards regression models. We used California emergency department and hospitalization databases to identify patients with SCD with intracranial hemorrhage, gastrointestinal (GI) bleeding, hemophthalmos, gross hematuria, epistaxis, menorrhagia, and other bleeding events. The cumulative incidence of any first bleeding event at age 40 years was 21% (95% confidence interval [CI], 19.8%-22.3%), increasing with age to 41% by age 60 years (95% CI, 38.8%-43.1%). The majority of bleeding events were GI (41.6%), particularly from the upper GI tract. A higher bleeding risk was associated with increased frequency of hospitalization (hazard ratio [HR], 2.16; 95% CI, 1.93-2.42), venous thromboembolism 180 days before bleeding event (HR, 4.24; 95% CI, 2.86-6.28), osteonecrosis of the femoral head (HR, 1.25; 95% CI, 1.08-1.46), and ischemic stroke (HR, 1.65; 95% CI, 1.20-2.26). Bleeding was also associated with a twofold increased risk for death (HR, 2.09; 95% CI, 1.82-2.41) adjusted for other SCD-related complications. Our novel finding of a high incidence of bleeding in patients with SCD, particularly from the upper GI tract, suggests that patients with SCD may be predisposed to bleeding, with possible etiologies including increased use of nonsteroidal anti-inflammatory drugs, mucosal infarction from vascular occlusion by sickled red blood cells, and increased stress ulceration from frequent hospitalization.
出血是镰状细胞病(SCD)的一种已知并发症,包括出血性中风、血尿和玻璃体出血。然而,SCD患者出血事件的发生率尚未得到充分描述。我们开展了一项基于人群的回顾性研究,调查了1991年至2014年间6423例SCD患者出血的累积发生率。我们还使用Cox比例风险回归模型研究了与出血相关的危险因素以及出血对死亡率的影响。我们利用加利福尼亚急诊科和住院数据库来确定患有颅内出血、胃肠道(GI)出血、眼球内出血、肉眼血尿、鼻出血、月经过多及其他出血事件的SCD患者。40岁时任何首次出血事件的累积发生率为21%(95%置信区间[CI],19.8%-22.3%),随年龄增长至60岁时增至41%(95%CI,38.8%-43.1%)。大多数出血事件为胃肠道出血(41.6%),尤其是上消化道出血。较高的出血风险与住院频率增加(风险比[HR],2.16;95%CI,1.93-2.42)、出血事件前180天发生静脉血栓栓塞(HR,4.24;95%CI,2.86-6.28)、股骨头骨坏死(HR,1.25;95%CI,1.08-1.46)和缺血性中风(HR,1.65;95%CI,1.20-2.26)相关。在对其他SCD相关并发症进行校正后,出血还与死亡风险增加两倍相关(HR,2.09;95%CI,1.82-2.41)。我们关于SCD患者出血发生率高,尤其是上消化道出血发生率高的新发现表明,SCD患者可能易发生出血,可能的病因包括非甾体类抗炎药使用增加、镰状红细胞血管阻塞导致的黏膜梗死以及频繁住院导致的应激性溃疡增加。